Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately define subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy for these cancers.Speaker 2: (00:32) Could you provide a brief background about yourself? Speaker 2: (01:12) Would you give us an overview of the PM3CX test? Speaker 2: (03:02) Which patients should have this testing?  Speaker 2: (05:14) Is this test qualitative and RNA? Speaker 2: (06:35) After determining if it's primary mediastinal large B-cell lymphoma or diffuse large B-cell lymphoma, does the test identify the cell of origin? Speaker 2: (08:09) For patients diagnosed with diffuse large B-cell lymphoma, what are the treatment recommendations? Speaker 2: (09:04)Are there any other insights about this test that you'd like to share?

Ver todos los episodios